Most platforms marketed as pharmacovigilance software can store, route, and log a case. Far fewer can demonstrably reduce case-level risk rather than simply organizing it into a searchable queue. The difference shows up in specific, testable details, not in a feature list.
What actually matters
Validation timing. Does the system check case data against ICH E2B(R3) and regional gateway rules in real time, as data is entered, or only right before final submission? Real-time checks catch errors when they're cheap to fix.
Coding methodology. Is MedDRA coding pulled from the actual database hierarchy and cross-checked against historical precedent, or does it depend on individual reviewer judgment and memory?
Case quality signal timing. Does every case get a completeness and quality score before it reaches gateway submission, or is quality only discovered reactively, through a query that comes back later?
Audit trail depth. Does the system log reasoning and confidence alongside actions, or just a timestamp confirming something happened? An inspector wants to understand why a decision was made, not just that it occurred.
Pattern visibility. When a case triggers a query or rejection, does the platform help identify whether the same root cause is recurring across other cases, or does each instance get handled in isolation?
Why this matters more than a feature checklist
Two platforms can list nearly identical capabilities and perform very differently once real case volume and complexity hit them in practice — the depth behind each feature, not its presence, is what actually determines case quality and inspection defensibility.
How Cloudbyz approaches this
Cloudbyz's pharmacovigilance tools validate in real time, ground coding in the actual MedDRA database with historical fallback, score every case proactively before submission, and surface recurring patterns across the full caseload rather than treating each query as an isolated fix.
See how Cloudbyz's PV platform performs against this evaluation lens — book a demo
